Article Details
Retrieved on: 2018-04-13 15:52:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>SOUTH SAN FRANCISCO, Calif., April 14, 2018 /PRNewswire/ -- NGM Bio, a leading biotech company developing a portfolio of clinical-stage product candidates that modulate novel or previously intractable targets implicated in metabolic and other serious diseases, today announced data from a Phase ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here